Catalyst
Slingshot members are tracking this event:
Acadia (ACAD) Initiates Phase 2 ADVANCE Study Analyzing Nuplazid in Patients with Negative Symptoms of Schizophrenia
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
ACAD |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 15, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Advance, Nuplazid, Negative Symptoms Of Schizophrenia